Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

TenNor Therapeutics

TenNor Therapeutics
2013 FOUNDED
PRIVATE STATUS
Series B LATEST DEAL TYPE
$25M LATEST DEAL AMOUNT
8 INVESTORS
Description

Provider oif a drug discovery platform designed to develop innovative drugs for infectious disease area. The company's platform offers a multi targeting, strong, globally protected product development portfolio for treating gastrointestinal tract infection, prosthetic joint infection, bacterial vaginosis , multidrug resistant tuberculosis, enabling users to get drugs that meet the unmet needs of treating different infectious diseases.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 218 Xinghu Street
  • Building B2, Room 711, Suzhou Industrial Park
  • Suzhou, 215123
  • China

+86 0512 0000 0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore TenNor Therapeutics’s full profile, request a free trial.

TenNor Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Early Stage VC (Series B) 19-Sep-2016 $25M 00.00 Completed Generating Revenue
2. Grant 01-Feb-2016 Completed Startup
1. Early Stage VC Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

TenNor Therapeutics Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Frontline BioVentures Venture Capital Minority 000 0000 000000 0
Northern Light Venture Capital Venture Capital Minority 000 0000 000000 0
Oriza Holdings Fund of Funds Minority 000 0000 000000 0
Relativity Capital PE/Buyout Minority 000 0000 000000 0
WuXi Healthcare Ventures Corporate Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »

TenNor Therapeutics Executive Team (4)

Name Title Board
Seat
Contact
Info
Zhenkun Ma Ph.D Founder, Chief Executive Officer & Board Member
Emily Chen Director, Finance
Ying Yuan Ph.D Vice President, Biology
Xiaomei Wang Vice President, Clinical Operations

TenNor Therapeutics Board Members (6)

Name Representing Role Since Contact
Info
Allen Chao Ph.D Newport Healthcare Advisors Board Member 000 0000
Edward Hu Ph.D WuXi Healthcare Ventures Board Member 000 0000
Feng Deng Northern Light Venture Capital Board Member 000 0000
Lianyong Chen Ph.D Frontline BioVentures Board Member 000 0000
Morton Meyerson 2M Companies Board Member 000 0000
You’re viewing 5 of 6 board members. Get the full list »